Sunday, February 5, 2023
  • About Us
  • Contact Us
KsaWeekly.com
  • News
  • Business
  • Finance
  • Technology
  • Lifestyle
  • Middle East
  • Press Release
Submit a News Release
No Result
View All Result
KsaWeekly.com
Submit PR
Home Press Release

Plasma Fractionation Market Worth $46.9 Billion by 2029 – Exclusive Report by Meticulous Research®

Press Room by Press Room
August 13, 2022
in Press Release
Plasma Fractionation Market Worth $46.9 Billion by 2029 – Exclusive Report by Meticulous Research®
Share on FacebookShare on Twitter


 


(EMAILWIRE.COM, August 13, 2022 ) According to a new market research report, “Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) – Global Forecast to 2029”, published by Meticulous Research®, the plasma fractionation market is expected to grow at a CAGR of 7.1% from 2022 to reach $46.9 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117

The separation, extraction, and purification of specific components from the plasma are called the fractionation process. The products extracted from the plasma are used for treating various disorders. Immunoglobulins are useful in treating autoimmune diseases and increasing the immune response. Clotting factors are used to treat blood disorders such as hemophilia and albumins, which are useful in cases of depleted albumin levels or during fluid loss. As the prevalence of hemophilia and autoimmune disease increases, the demand for plasma-derived products will rise in the coming years.

Impact of COVID-19 on the Plasma Fractionation Market

Limited data suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness. Therefore, evaluating these therapies in the context of a clinical trial and expanded access program is important. Hence, well-controlled clinical trials are conducted to evaluate the safety and efficacy of plasma treatment. Some of these include;

In China, in February 2020, an interventional clinical trial was started to evaluate the efficacy of intravenous immunoglobulin therapy in patients with severe 2019- nCoV pneumonia with 80 participants.
In France, in April 2020, an interventional clinical trial was started regarding early treatment with polyvalent immunoglobulin in managing acute respiratory distress syndrome associated with SARS-CoV-2 infections. Over 138 participants were enrolled in the study.
In the U.S., in April 2020, a clinical trial ‘The COVID-IG trial: intramuscular (IM) injection of COVID-19-convalescent hyperimmune immunoglobulin (COVID-IG) to prevent SARS-CoV-2 infection in high-risk persons’ was carried out.
Thus, the clinical trials, being an initial part of the evolution of treatment during COVID-19, positively impact the plasma fractionation market.

The plasma fractionation market is segmented based on product, application, and end user. The study also evaluates industry competitors and analyzes the regional and country markets.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5117

Based on product, the immunoglobulins segment is estimated to account for the largest share of the plasma fractionation market in 2022. The segment is also expected to grow at the highest CAGR during the forecast. The large share is mainly attributed to the adoption of plasma-derived immunoglobulins to treat various immunological disorders such as autoimmunity diseases, primary and secondary immunodeficiency, and neurological disorders. Further, the COVID-19 disease resulted in the growth of studies regarding the use of hyper immunoglobulins derived from COVID-19 recovered patients’ plasma to treat the disease.

Based on application, the neurology segment is expected to grow at the highest CAGR during the forecast period due to the rise in the prevalence of neurological disorders and plasma-derived products for treating these disorders.

Based on end user, the hospitals & clinics segment is estimated to command the largest share of the market in 2022. The growing need for therapies for immunodeficiency disorders, the growing number of hospitals & healthcare expenditure, and the largest consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.

Geographically, North America is estimated to dominate the overall plasma fractionation market in 2022, followed by Europe and Asia-Pacific. The growing number of respiratory diseases will increase the adoption of coagulation factors, which drives the market for plasma fractionation in North America. Also, a surge in consumption of immunoglobulins, an increase in plasma collection centers, the capability to supply plasma due to the feasibility of plasma collection & distribution, and the presence of key players contribute to the regional market’s growth.

Quick Buy – “Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) – Forecast to 2029” Research Report: https://www.meticulousresearch.com/Checkout/75893588

However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the Asia-Pacific market are the rising consumption of plasma-derived products, the strategic developments made by the companies in this region, the presence of leading players, and contract fractionation agreements between the countries.

The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments in the industry’s leading market participants over the past four years (2019–2022). In recent years, the plasma fractionation market has witnessed several product approvals, new product launches, partnerships, agreements, & collaborations, expansions, and acquisitions. For instance, in February 2022, Grifols, S.A. (Spain) entered into an agreement with Endpoint Health, Inc. (U.S.) to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. Also, in August 2021, Octopharma AG (Switzerland) received U.S. FDA approval for Octagam 10% [Immune Globulin Intravenous (Human)] for the treatment of adult dermatomyositis (DM).

Some of the key players operating in this market are CSL Limited (Australia), Grifols, S.A. (Spain), Octopharma AG (Switzerland), Kedrion S.P.A. (Italy), Shire plc (U.K.), Biotest AG (Germany), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Ltd (U.K.), Japan Blood Products Organization (Japan), and Intas Pharmaceuticals Ltd. (India).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/plasma-fractionation-market-5117



Source link

Previous Post

Over-the-Top Services Market Size Gaining : USD 156.9 billion by 2024

Next Post

OmanNews.Club™ Adds to Arab Newswire Media Lists for Press Release Distribution to GCC/MENA Countries

RECOMMENDED NEWS

Saudi Aramco Entrepreneurship Center (Wa’ed) leads $50 million Series B round in Islamic fintech Wahed

8 months ago
Electric Construction Equipment Market to Hit USD 241.20 Bn. at Growth Rate of 6.8 percent by 2029

Electric Construction Equipment Market to Hit USD 241.20 Bn. at Growth Rate of 6.8 percent by 2029

2 weeks ago

Saudi fashion designer 'shocked' and 'proud' to see Duchess of Cornwall wearing his design – Arab News

8 months ago

5G Industrial IOT Market To 2026 Industry Outlook, Growth Opportunities, Trends | Market Growth

4 months ago

BROWSE BY CATEGORIES

  • Business
  • Finance
  • Lifestyle
  • Middle East
  • News
  • Press Release
  • Technology

POPULAR NEWS

  • ZainTech partners with LigaData to deliver data-driven digital services in MENA

    ZainTech partners with LigaData to deliver data-driven digital services in MENA

    0 shares
    Share 0 Tweet 0
  • تم إطلاق VOYAH FREE في أوروبا وتم افتتاح معرض VOYAH.

    0 shares
    Share 0 Tweet 0
  • Saudi Arabia’s NuqtahNFT and ConsenSys partner to empower Web 3 startups

    0 shares
    Share 0 Tweet 0
  • Vidliz Expands Its Data-Driven Online Marketing Services in the Middle East

    0 shares
    Share 0 Tweet 0
  • قد يؤدي استهلاك الجوز إلى إبطاء تطوّر السرطان

    0 shares
    Share 0 Tweet 0

KSA Weekly™ publishes and aggregates business, socio-economic, Tech and industrial news on Saudi Arabia, Middle East and North Africa (MENA).

We provide press release distribution to media in the Kingdom of Saudi Arabia, the Arab world and the GCC/MENA regions. To send your press release, contact us today.

Recent News

Recent Posts
  • Data Center Power Market Projected to Gain $26.1 billion by 2025
  • Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024
  • Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026
  • Industrial PC Market Worth $6.6 billion in 2028 at a CAGR of 5.5%
  • UHT Processing Market Statistics, Growth, Trends & Forecasts

Category

News

Business

Finance

Technology

Lifestyle

Middle East

Press Releases

Subscribe to Our Newsletter

    KSA Weekly ™ is part of GroupWeb Media Network. © 2023 GroupWeb Media LLC

    • About Us
    • Contact Us
    • Submit a Press Release
    No Result
    View All Result
    • News
    • Business
    • Finance
    • Technology
    • Lifestyle
    • Middle East
    • Press Release

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.